Geode Capital Management
APUS

Geode Capital Management’s Apimeds Pharmaceuticals US APUS Stock Holding History

Geode Capital Management’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.6K Sell
3,511
-494
-12% -$6.73K ﹤0.01% 4316
2026
Q1 		$71.7K Buy
4,005
+516
+15% +$8.31K ﹤0.01% 4224
2025
Q4 		$57.2K Buy
3,489
+414
+13% +$8.83K ﹤0.01% 4209
2025
Q3 		$54.7K Buy
+3,075
New +$57K ﹤0.01% 4271

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Geode Capital Management's APUS Position: Q2 2026 in Review

Geode Capital Management reduced its Apimeds Pharmaceuticals US (APUS) stake by 12% in Q2 2026, selling an estimated $6.73K and leaving 3,511 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4316.

Geode Capital Management first reported a position in APUS in Q3 2025 and has held it in 4 quarters since. The position peaked at $71.7K in Q1 2026. 6 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

  • Geode Capital Management held 3,511 shares of Apimeds Pharmaceuticals US worth $31.6K as of Q2 2026.
  • Geode Capital Management sold 494 Apimeds Pharmaceuticals US shares in Q2 2026, an estimated $6.73K.
  • Apimeds Pharmaceuticals US made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4316 holding.
  • Geode Capital Management first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and has held it in 4 quarters since.
  • Geode Capital Management's Apimeds Pharmaceuticals US position peaked at $71.7K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.